(AKBA) Akebia Ther - Overview
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NASDAQ (USA) | Market Cap: 279m USD | Total Return: -66.1% in 12m
Avg Turnover: 5.01M
Qual. Beats: 0
Rev. Trend: 51.2%
Qual. Beats: 0
Warnings
Interest Coverage Ratio 0.1 is critical
Altman Z'' -15.00 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
Akebia Therapeutics, Inc. is a biopharmaceutical firm headquartered in Cambridge, Massachusetts, specialized in developing and marketing treatments for kidney-related conditions. The company’s primary portfolio includes Vafseo (vadadustat), an oral treatment for anemia associated with chronic kidney disease (CKD), and Auryxia, a ferric citrate product used to manage serum phosphorus levels and iron deficiency anemia in CKD patients. Beyond its commercial assets, Akebia is advancing clinical-stage candidates such as AKB-9090 for acute kidney injury and AKB-10108 for neonatal retinopathy.
The company operates within the biotechnology sector, where business models often rely on extensive licensing and collaboration agreements to manage the high costs of global clinical trials and distribution. Akebia maintains several such partnerships, notably with Mitsubishi Tanabe Pharma Corporation for Asian markets and CSL Vifor. Investors may find it useful to review the detailed financial projections for these partnerships on ValueRay.
Biotechnology firms focusing on renal care target a specialized market segment characterized by high regulatory scrutiny and a reliance on dialysis-dependent patient populations. Akebia’s strategy involves leveraging its hypoxia-inducible factor (HIF) platform to address unmet needs in both dialysis and non-dialysis settings.
- FDA approval of Vafseo for dialysis patients drives primary commercial revenue growth
- Auryxia patent expiration and generic competition threaten core product cash flow
- Medicare reimbursement policy changes impact dialysis provider utilization of Vafseo
- Strategic partnerships with CSL Vifor influence market penetration and royalty income
- Clinical trial data for pipeline candidates determines long-term valuation beyond kidney disease
| Net Income: -20.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.17 > 0.02 and ΔFCF/TA 27.79 > 1.0 |
| NWC/Revenue: 29.95% < 20% (prev 60.87%; Δ -30.92% < -1%) |
| CFO/TA 0.17 > 3% & CFO 60.4m > Net Income -20.5m |
| Net Debt (-111.6m) to EBITDA (3.16m): -35.29 < 3 |
| Current Ratio: 1.40 > 1.5 & < 3 |
| Outstanding Shares: last quarter (267.0m) vs 12m ago 10.53% < -2% |
| Gross Margin: 80.87% > 18% (prev 0.73%; Δ 8.01k% > 0.5%) |
| Asset Turnover: 69.09% > 50% (prev 59.61%; Δ 9.48% > 0%) |
| Interest Coverage Ratio: 0.09 > 6 (EBITDA TTM 3.16m / Interest Expense TTM 21.1m) |
| A: 0.19 (Total Current Assets 243.5m - Total Current Liabilities 173.9m) / Total Assets 362.5m |
| B: -4.67 (Retained Earnings -1.69b / Total Assets 362.5m) |
| C: 0.01 (EBIT TTM 1.88m / Avg Total Assets 336.4m) |
| D: -5.05 (Book Value of Equity -1.69b / Total Liabilities 335.1m) |
| Altman-Z'' = -19.23 = D |
| DSRI: 0.81 (Receivables 62.5m/61.5m, Revenue 232.4m/184.9m) |
| GMI: 0.90 (GM 80.87% / 72.72%) |
| AQI: 1.02 (AQ_t 0.32 / AQ_t-1 0.31) |
| SGI: 1.26 (Revenue 232.4m / 184.9m) |
| TATA: -0.22 (NI -20.5m - CFO 60.4m) / TA 362.5m) |
| Beneish M = -3.31 (Cap -4..+1) = AA |
As of May 30, 2026, the stock is trading at USD 1.02 with a total of 2,701,021 shares traded.
Over the past week, the price has changed by +0.00%,
over one month by -25.00%,
over three months by -22.14% and
over the past year by -66.11%.
Akebia Ther has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy AKBA.
- StrongBuy: 3
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 4.2 | 311.8% |
P/E Forward = 28.7356
P/S = 1.2004
P/B = 10.2404
Revenue TTM = 232.4m USD
EBIT TTM = 1.88m USD
EBITDA TTM = 3.16m USD
Long Term Debt = 36.4m USD (from longTermDebt, last quarter)
Short Term Debt = 12.5m USD (from shortTermDebt, last quarter)
Debt = 51.0m USD (corrected: LT Debt 36.4m + ST Debt 12.5m) + Leases 2.13m
Net Debt = -111.6m USD (calculated: Debt 51.0m - CCE 162.6m)
Enterprise Value = 167.4m USD (279.0m + Debt 51.0m - CCE 162.6m)
Interest Coverage Ratio = 0.09 (Ebit TTM 1.88m / Interest Expense TTM 21.1m)
EV/FCF = 2.79x (Enterprise Value 167.4m / FCF TTM 60.0m)
FCF Yield = 35.85% (FCF TTM 60.0m / Enterprise Value 167.4m)
FCF Margin = 25.82% (FCF TTM 60.0m / Revenue TTM 232.4m)
Net Margin = -8.83% (Net Income TTM -20.5m / Revenue TTM 232.4m)
Gross Margin = 80.87% ((Revenue TTM 232.4m - Cost of Revenue TTM 44.5m) / Revenue TTM)
Gross Margin QoQ = 76.43% (prev 78.80%)
Tobins Q-Ratio = 0.46 (Enterprise Value 167.4m / Total Assets 362.5m)
Interest Expense / Debt = 41.36% (Interest Expense 21.1m / Debt 51.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = 1.49m (EBIT 1.88m * (1 - 21.00%))
Current Ratio = 1.40 (Total Current Assets 243.5m / Total Current Liabilities 173.9m)
Debt / Equity = 1.86 (Debt 51.0m / totalStockholderEquity, last quarter 27.4m)
Debt / EBITDA = -35.29 (Net Debt -111.6m / EBITDA 3.16m)
Debt / FCF = -1.86 (Net Debt -111.6m / FCF TTM 60.0m)
Total Stockholder Equity = 32.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -6.10% (Net Income -20.5m / Total Assets 362.5m)
RoE = -1.19% (Net Income TTM -20.5m / Total Stockholder Equity 1.73b)
RoCE = 0.11% (EBIT 1.88m / Capital Employed (Equity 1.73b + L.T.Debt 36.4m))
RoIC = 3.86% (NOPAT 1.49m / Invested Capital 38.5m)
WACC = 13.89% (E(279.0m)/V(330.0m) * Re(10.45%) + D(51.0m)/V(330.0m) * Rd(41.36%) * (1-Tc(0.21)))
Discount Rate = 10.45% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 82.22 | Cagr: 16.20%
[DCF] Terminal Value 58.60% ; FCFF base≈60.0m ; Y1≈60.3m ; Y5≈63.8m
[DCF] Fair Price = 2.32 (EV 511.8m - Net Debt -111.6m = Equity 623.4m / Shares 268.3m; r=13.89% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: 51.24 | Revenue CAGR: 7.21% | SUE: 0.18 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.03 | Chg30d=N/A | Revisions=+20% | Analysts=2
EPS next Quarter (2026-09-30): EPS=-0.03 | Chg30d=N/A | Revisions=+20% | Analysts=2
EPS current Year (2026-12-31): EPS=-0.10 | Chg30d=N/A | Revisions=+20% | GrowthEPS=-425.0% | GrowthRev=-12.5%
EPS next Year (2027-12-31): EPS=-0.19 | Chg30d=-100.00% | Revisions=+20% | GrowthEPS=-81.0% | GrowthRev=-22.6%
[Analyst] Revisions Ratio: +20%